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ABSTRACT
Pseudomonas aeruginosa is a pathogen that often infects patients who are either immunocompromised or
have local defects in host defences. It is known that cystic ﬁbrosis (CF) patients are sometimes infected
with certain clonal isolates. It is not clear whether these clonal isolates also infect non-CF patients and
whether clonality of isolates occurs in other patient groups. The aim of this study was to investigate
P. aeruginosa diversity and the occurrence of clones within ﬁve distinct paediatric patient groups
susceptible to P. aeruginosa infection. P. aeruginosa isolates were cultured from 157 patients (CF ﬁrst
infection (CF-1 group) (29); CF chronic infection (CF-chronic group) (27); urinary tract infection (34);
chronic suppurative otitis media (43); and intensive-care hospitalization ⁄ immunodeﬁciency (24)).
All 202 phenotypically different isolates were tested for antimicrobial resistance and further typed
by pulsed-ﬁeld gel electrophoresis. Simpson’s diversity index was calculated for the ﬁve groups.
CF-chronic patients carried the highest number of distinct P. aeruginosa phenotypes and genotypes per
culture. Isolates from the CF-chronic group were signiﬁcantly less diverse than those from the other
groups. A group of clonal isolates was observed among patients from the CF-chronic and CF-1 groups.
These or different clonal isolates were not encountered among the three other patient groups. No
characteristic resistance pattern could be identiﬁed among isolates from the distinct patient groups and
among the clonal isolates. In conclusion, isolates of the CF-chronic group were less diverse than those in
the other patient groups with P. aeruginosa infection; clonal isolates were not encountered in non-CF
patients. Transmission of clonal CF isolates to other patient groups was not observed.
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INTRODUCTION
Pseudomonas aeruginosa is a common cause of
chronic pulmonary infections in patients with
cystic ﬁbrosis (CF). There are several hypotheses
concerning the increased susceptibility to P. aeru-
ginosa infections in CF patients. It has been
suggested that cells with mutant cystic ﬁbrosis
transmembrane regulator (CFTR) protein are not
able to bind, internalize and kill P. aeruginosa [1].
A decreased volume of the pulmonary periciliary
liquid layer due to electrolyte disturbances leads
to mucus with increased viscosity and impaired
clearance. The anaerobic conditions in the mucus
layer upregulate alginate production, and muta-
tions promote a switch from non-mucoid
to mucoid phenotypes of P. aeruginosa that are
difﬁcult to eradicate [2,3].
P. aeruginosa is a pathogen that infects patients
who are either immunocompromised or have
local defects in host defences. Once it has attached
to the epithelium, P. aeruginosa produces type III
secretion products that interfere with cell signal
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transduction. Tissue destruction and immune
response are promoted by extracellular products
such as elastase, phospholipase C and exotoxin A
[4,5]. In CF patients, unique P. aeruginosa isolates
responsible for ﬁrst acute infection are probably
picked up from the environment. In contrast, CF
patients with chronic P. aeruginosa infection often
share common bacterial genotypes that are either
selected or transmitted among patients, so-called
‘epidemic strains’ or ‘clones’ [6–8]. P. aeruginosa
might adapt to the CF host environment by
suppression of virulence factor production to
evade host phagocytic defence [9,10].
As well as CF patients, several other paediatric
patient groups are highly susceptible to P. aeru-
ginosa infection. Children with chronic suppura-
tive otitis media (CSOM) have damaged inner ear
epithelium as a result of previous episodes of acute
otitis media. P. aeruginosa adheres to the damaged
epithelium and might form a bioﬁlm [11]. The
same principle applies to children with anatomical
or neurological abnormalities of the urinary tract
system. Intermittent urethral catheterization or
indwelling catheters may damage the epithelial
lining of the urinary tract, and introduce P. aeru-
ginosa to the urinary tract, sometimes in a bioﬁlm
mode of growth [12]. Chronic or recurrent infec-
tions with P. aeruginosa occur frequently among
these patients, and these bacteria are often derived
from a hospital source. In intensive-care units
(ICUs), P. aeruginosa incidentally causes pneumo-
nia or bloodstream infections. P. aeruginosa pneu-
monia in ventilated patients is related to
mechanical injury to the respiratory epithelium,
and facilitated by micro-aspiration of infected oral
and gastric contents during intubation [5]. Also,
primary or secondary immunodeﬁciency (ID)
renders patients highly prone to P. aeruginosa
infection. Not only is the recruitment of neutroph-
ils a major component of the protective host
response to P. aeruginosa, but T-lymphocyte-med-
iated immunity also appears to play an important
role in host defence against P. aeruginosa [13,14].
It is unclear whether speciﬁc clonality and
adaptation of P. aeruginosa isolates occurs in the
above-mentioned non-CF patient groups with
increased susceptibility to P. aeruginosa infection.
Several studies have been performed to detect
P. aeruginosa transmission or clonality within a
hospital by genotyping; however, in most of these
studies, no large distinct patient groups were
compared [15–17]. Some of these studies de-
scribed clonal outbreaks with multidrug-resistant
P. aeruginosa in ICUs or urology units [18]. On the
other hand, CF research groups investigated
isolates from sputa of CF patients to establish
P. aeruginosa clonality, but most of them did not
compare these isolates with other isolates from
large, standardized patient groups [6–8,19].
Therefore, our aim was to investigate the occur-
rence of P. aeruginosa clones within and among
ﬁve distinct paediatric patient groups susceptible
to P. aeruginosa infection.
MATERIALS AND METHODS
Patients and setting
Five groups of paediatric patients with P. aeruginosa infection
participated in this study. P. aeruginosa infections in these
patient groups account for c. 80–90% of P. aeruginosa infec-
tions in our hospital. The ﬁrst group consisted of 29 CF
patients with a ﬁrst respiratory culture positive for P. aerugin-
osa (CF-1). The second group consisted of 27 CF patients with
chronic P. aeruginosa infection, deﬁned as having had P. aeru-
ginosa in >50% of all cultures from sputa or cough swabs in the
last year, according to Lee’s criteria (CF-chronic) [20]. Thirty-
four patients in the third group experienced recurrent urinary
tract infection (UTI) and ⁄ or colonization with P. aeruginosa,
predominantly because of underlying neurological or anatom-
ical abnormalities. The fourth group comprised 43 patients
with CSOM from whom P. aeruginosa was isolated. The last
group comprised 24 patients who acquired P. aeruginosa
infection at the ICU and patients with underlying primary or
secondary ID (ICU ⁄ ID).
All patients had regular follow-up at the Wilhelmina Chil-
dren’s Hospital, Utrecht, The Netherlands, a tertiary-referral
centre. Patients were seen in both the inpatient and outpatient
clinics, located in the same building. Some of the patients from
the UTI group and the CSOM group participated in a trial with
regular collection of culture specimens. Outpatients and inpa-
tientswere not separated; however,most inpatientswere placed
inprivate roomsor smallwards, except for the ICU. From2005, a
strict CF segregation policy was introduced. P. aeruginosa
isolates were retrospectively and prospectively collected
routinely, or according to indication, between September 2004
and May 2006. For analysis, the ﬁrst positive culture specimen
available per patient was included.
Cultures and susceptibility testing
Patient specimens (sputa, swabs, catheter urine and respira-
tory secretions) were cultured onto appropriate selective and
non-selective media and examined at 24 and 48 h for the
presence of P. aeruginosa on the basis of morphological
features. P. aeruginosa was identiﬁed by standard microbio-
logical methods on solid media and by a positive oxidase
reaction. Further identiﬁcation of each morphologically
distinct colony (mucoid and non-mucoid) was performed by
the BD Phoenix automated system (BD Diagnostic Systems,
Sparks, MD, USA), which included antibiotic susceptibility
testing (NMIC ⁄ ID-panel). In addition, in all cases, susceptibil-
ity testing was also performed by disk diffusion using Rosco
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(Neo-Sensitabs) tablets (A ⁄ S Rosco, Taastrup, Denmark).
When identiﬁcation by the Phoenix system was ambiguous,
an API 20NE (bioMerieux, Marcy L’Etoile, France) was
performed; when susceptibility testing yielded ambiguous
results, an MIC was determined by Etest (AB Biodisk, Solna,
Sweden). Susceptibility testing included aminoglycosides,
b-lactams (piperacillin–tazobactam, meropenem and ceftazi-
dime), polymyxins and ﬂuoroquinolones, and results were
interpreted according to CLSI breakpoints. Multidrug
resistance was deﬁned as resistance to more than one of the
antibiotic classes mentioned above, as suggested by Paterson
[18]. Single colonies of all phenotypically distinct isolates were
stored at )80ºC until handling.
Pulsed-ﬁeld gel electrophoresis (PFGE)
Pulsed ﬁeld gel electrophoresis (PFGE) was performed
because of its high discriminatory ability, as described previ-
ously [21,22]. Brieﬂy, 2% melting agarose plugs (Sigma A-
4018) containing bacterial suspension in an equal volume were
incubated for 24 h at 56C with 10 lL of proteinase K
(50 mg ⁄mL) in 1 mL of EDTA-Sarcosine (ES) buffer. After
washing three times with TRIS, NaCl, MgCl2, dithiotreitol
(NE) buffer with Bovine Serum Albumin (BSA), bacterial DNA
was digested for 24 h at 37C with the restriction enzyme SpeI
(New England Biolabs, Ipswich, MA, USA). Electrophoresis
was performed in agarose (1%) gel (Seakem Gold) in a
clamped homogeneous electric ﬁeld system (Chef DR II
system; Bio-Rad Laboratories, Hercules, CA, USA). A lambda
ladder control marker (New England Biolabs) was inserted.
After electrophoresis, the gel was stained with ethidium
bromide and photographed under UV light with Gel Doc EQ
(Bio-Rad laboratories). The macrorestriction band patterns
were analyzed by QUANTITY ONE and FINGERPRINTING
software (Bio-Rad), and examined visually. Cluster analysis
was carried out using Dice coefﬁcients of pattern similarity
with the unweighted pair group using mathematical average
(UPGMA) algorithm, with a tolerance limit of 1% for band
migration distance. Isolates were considered to be probably
related when having a pattern with ‡80% homology. A clone
was deﬁned as genetically related isolates that are indistin-
guishable or probably related, as investigated by PFGE [23].
Statistics
To compare parameter means with 95% CIs among distinct
patient categories, the independent-samples Student t-test was
used. All statistical calculations were performed using SPSS
version 12.0 (SPSS, Chicago, IL, USA).
To estimate diversity of the P. aeruginosa isolates in the ﬁve
distinct groups, Simpson’s diversity index with 95% CIs was
calculated using RIDOM EPICOMPARE software [24,25]. Calcula-
tions were performed taking into account all phenotypically
different isolates per group. A score of 1 indicates maximum
diversity, and a score of 0 indicates no diversity.
RESULTS
Patients, and P. aeruginosa phenotypes and
genotypes
Two hundred and two P. aeruginosa isolates from
157 patients were cultured. Table 1 shows the
mean number of phenotypically distinct isolates
per culture. This number is higher for the
CF-chronic group than for all the other groups
(p <0.001 for all groups). Mucoid isolates were
observed only in the CF patients. As the number
of genotypes per culture was lower than the
number of phenotypes, the phenotypically differ-
ent isolates did not all have a distinct genotype.
The number of genotypes per culture in the
CF-chronic group was higher than that in the
other groups (CF-1 (p 0.007), UTI (p 0.079),
CSOM (p <0.001) and ICU ⁄ ID (p 0.006)).
A group of isolates with ‡80% homology was
observed within the CF-chronic and CF-1 groups.
Fourteen of 27 patients (52%) from the CF-chronic
group carried such isolates, which were regarded
as clonal (Fig. 1 shows some of the isolates with
‡80% homology). Two patients from the CF-1
group acquired P. aeruginosa infection with the
clonal genotype. These clonal isolates were not
encountered in cultures from patients in the UTI,
CSOM and ICU ⁄ ID groups. Other genotypically
related isolates (‡80% homology) were occasion-
ally encountered in cultures from patients in the
other groups (Table 1). One patient from the UTI
group and one patient from the ICU ⁄ ID group
carried a related isolate.
Table 1. Patient and isolate data concerning the ﬁve study groups
CF-1 CF-chronic UTI CSOM ICU ⁄ ID
No. of patients 29 27 34 43 24
Mean age (years) at Pseudomonas aeruginosa isolation for analysis (95% CI) 7.25 (5.57–8.94) 12.35 (10.71–13.99) 5.77 (3.91–7.63) 6.34 (5.30–7.37) 6.37 (4.20–8.53)
No. of isolates with mucoid phenotype 2 10 – – –
No. of phenotypically different isolates 36 56 42 44 24
Mean number of phenotypically different isolates per culture (95% CI) 1.21 (1.05–1.36) 2.07 (1.66–2.48) 1.24 (1.02–1.45) 1.02 (0.98–1.07) 1.00
Mean number of genotypically different isolates per culture (95% CI) 1.03 (0.96–1.11) 1.41 (1.13–1.68) 1.15 (0.99–1.29) 1.00 1.00








1 · 2 1 · 2
CF, cystic ﬁbrosis; CSOM, chronic suppurative otitis media; ICU, intensive-care unit; ID, immunodeﬁciency; UTI, urinary tract infection.
aTwo patients from the CF-1 group that carried clonal isolates and 14 patients from the CF-chronic group with clonal isolates.
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Measurement of P. aeruginosa diversity in each
patient group
Simpson’s diversity index (DI) demonstrated that
patients from the CF-chronic group carried sig-
niﬁcantly less diverse isolates (DI 0.90, 95% CI
0.85–0.95) than patients from the other groups.
With respect to diversity, isolates from CF-1
patients (DI 0.99) resembled UTI (DI 0.99),
CSOM (DI 1.00) and ICU ⁄ ID (DI 1.00) isolates.
In vitro resistance against anti-Pseudomonas
antibiotics
Susceptibility testing revealed in vitro resistance
to one or more of the tested antibiotics in 14.9% of
isolates (Table 2). Twenty-ﬁve (12.4%) isolates
were resistant to one anti-Pseudomonas antibiotic,
and ﬁve (2.5%) isolates were multidrug resistant;
however, no isolate was resistant to all evaluated
anti-Pseudomonas antibiotics. The highest percent-
age of resistance was found in the UTI group,
followed by the CSOM and CF-chronic groups.
These resistance rates did not differ signiﬁ-
cantly from those of the CF-1 and ICU ⁄ ID
groups (p 0.309). No characteristic resistance
pattern could be identiﬁed in the distinct patient
categories.
P. aeruginosa in chronically infected CF patients
The 14 carriers of the CF clone were signiﬁcantly
older than the 13 CF patients who carried strains
of other genotypes (14.52 ± 2.17 vs. 10.01 ± 4.53;
p 0.005). Within the group of 13 patients with
strains of other genotypes, two patients were
carrying strains of distinct, probably related,
genotypes. Clonal isolate carriers also had infec-
tions of longer duration, although not signiﬁ-
cantly longer (5.69 ± 3.20 vs. 4.25 ± 3.96; p 0.312).
The clonal genotype exhibited several phenotypic
expressions. It was observed that in some
patients, mucoid and non-mucoid isolates recov-
ered from the same patient belonged to the
common clone. In the CF-chronic group, both
patients infected with the clone and patients
infected with other genotypes carried, on average,
more than one phenotype and genotype per
culture. Patients carrying the clonal genotype
showed higher resistance rates than other geno-
type carriers (22.5% vs. 8.0%), but no uniform
resistance pattern was noted.
DISCUSSION
A large amount of diversity in phenotypic expres-
sion and resistance patterns of P. aeruginosa in ﬁve
distinct paediatric patient groups (157 patients)
with P. aeruginosa infection was observed. The
majority of P. aeruginosa isolates had a unique
genotype; however, the fact that a group of clonal
436.5 kb









Fig. 1. Macrorestriction patterns of some clonal isolates.
Table 2. In vitro resistance of all Pseudomonas aeruginosa isolates to major anti-Pseudomonas antibiotics
TOB CIP PIP CAZ COL TOB + PIP + CAZ + CIP TOB + PIP + CAZ CIP + PIP + CAZ Total resistance
CF-1 (N = 36) 1 (3) 1 (3) – – – 1 (3) – – 3 (8.3)
CF-chronic (N = 56) 2 (4) – 2 (4) 3 (5) – – 2 (4) – 9 (16.1)
UTI (N = 42) 4 (9) 2 (5) – 2 (5) – – – 2 (5) 10 (23.8)
CSOM (N = 44) – 6 (13) – – – – – – 6 (13.6)
ICU ⁄ ID (N = 24) – 2 (8) – – – – – – 2 (8.3)
Total (N = 202) 7 (3.5) 11 (5.4) 2 (1.0) 5 (2.5) – 1 (0.5) 2 (1.0) 2 (1.0) 30 (14.9)
All values are given as no. (%).
CF, cystic ﬁbrosis; CSOM, chronic suppurative otitis media; ICU, intensive-care unit; ID, immunodeﬁciency; UTI, urinary tract infection; TOB, tobramycin; CIP, ciproﬂoxacin;
PIP, piperacillin; CAZ, ceftazidime; COL, colistin.
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isolates was detected among CF patients but not
in patients with CSOM, UTIs or immunodeﬁcient
status, or who were hospitalized in ICUs, sug-
gests cross-infection, host speciﬁcity or a common
source [6,26]. The patients investigated in this
study were all prone to P. aeruginosa infection
because of underlying conditions. Because clonal
isolates were noticed among CF patients, and only
occasionally among the others, the factors
accounting for this clonality were sought.
First, the aetiology of P. aeruginosa infection
differs. CF is an intrinsic genetic disorder with
loss of CFTR function in epithelial cells.
The aetiology of P. aeruginosa infection in other
patients often involves epithelial damage, which
increases the possibility of P. aeruginosa binding
through its pili, and a condition of a continuem
between the environment and lungs, inner ear or
urinary tract. The speciﬁc condition in the CF
lung with defective CFTR, electrolyte abnormal-
ities, inﬂammation and hyperviscous mucus is
not comparable with other conditions. Neverthe-
less, the diversity in the CF-1 group resembles
that in the other non-CF patient groups. In CF
patients, the ﬁrst colonization with unique non-
mucoid forms might be eradicated successfully in
the early stage; however, recolonization often
occurs with the same or different genotype(s). In
later stages, eradication of the organism is rarely
achieved, because of hampered penetration of
antimicrobials, and chronic infection is the con-
sequence. Previous pulmonary infection with
unique P. aeruginosa isolates might predispose
the patient to be colonized by clonal isolates, as
does the speciﬁc CF lung status. This can be
illustrated by the fact that within the CF-1 group,
only two of 29 patients showed infection with the
clonal genotype. Both patients had mixed infec-
tion with another unique genotype. Regarding
P. aeruginosa infections in the other groups,
P. aeruginosa may be deﬁnitively or temporarily
eradicated by antimicrobial therapy; re-introduc-
tion might occur because of predisposing and
environmental factors. Adaptation of bacteria to
the host is possible if eradication is not successful
and bacteria stay in the host environment for a
longer period [10].
Second, interpatient contacts may facilitate
transmission of bacteria. For CF patients, this
has been proven in CF summer camps [27].
However, colonization with genotypically identi-
cal isolates has been documented for CF patients
who were separated from each other, suggesting a
possible common environmental source [6]. In
our hospital, strict CF patient segregation was
introduced in 2005. Most of the infections with
clonal isolates might have occurred before this
segregation. There is evidence that aerosol trans-
mission occurs via coughing; the modes of trans-
mission for CF patients are probably aerogenous,
via respiratory secretions or via contaminated
(respiratory) equipment or environment, with a
high transmission risk in comparison with the
transmission risk of patients with other infection
sites [26,28–30]. CF patients are not segregated
from other patients, and transmission of bacteria
between CF patients and other patients might
occur in the wards, recreational rooms or outpa-
tient clinics via hospital personnel, personal con-
tacts or contaminated environment; however, this
could not be proved with the current study
groups.
Clonal isolates probably have selective advan-
tages in colonizing CF patients. The capacity of
P. aeruginosa to adapt to its environment might
be applicable to the explanations above. Adap-
tation was examined by scoring the develop-
ment of antimicrobial resistance and mucoidity
in the study groups and, as in other studies,
different patterns of resistance were noticed
among clonal isolates [6,8]. Additionally, anti-
microbial resistance in both CF groups was not
higher than in the other groups. Mucoidity was
observed, but in a minority of isolates in the
CF-chronic group. Thus, in CF patients, another
mechanism must be responsible for the high
prevalence of clonal genotypes. Clonal CF iso-
lates differ among countries and CF centres
(unpublished data); consequently, various iso-
lates are able to become clonal isolates. Down-
regulation of virulence factor genes to evade the
host response has been observed in these clones
as an adaptation strategy; however, increased
virulence has been proved in other studies
[10,31]. Reduced virulence might explain the
decreased capacity to infect non-CF patients, as
no clonal isolate was observed in the non-CF
patient groups. Another survival strategy is
hypermutation,which is extremely prevalent in
CF isolates; however, hypermutability seemed
not to be more prevalent in clonal isolates
[32,33]. Genetic unravelling and performance of
virulence factor assays might contribute to an
understanding of the factors necessary for the
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organisms to become successful colonizers in CF
patients, but not in other patients.
The P. aeruginosa diversities estimated in this
study are based on PFGE typing, which has long
been regarded as the reference standard for
genotyping. PFGE seems to have even greater
discriminative ability than multilocus sequence
typing. However, isolates not designated as clonal
by PFGE might have a common ancestry that can
be visualized with multilocus sequence typing
[22,34]. Further studies with both older and novel
techniques might allow a better understanding of
the epidemiology of clones.
Only 2.5% of the studied P. aeruginosa isolates
possessed multidrug resistance. In general, resis-
tance against antimicrobials was low, being high-
est in the UTI group. In a 2005 nationwide
surveillance effort, the highest resistance rates
were also found among urology isolates, with
ciproﬂoxacin resistance rates of 10% (Nethmap
2006, Dutch Working Party on Antibiotic Policy
www.swab.nl). The somewhat higher (statisti-
cally non-signiﬁcant) resistance rates among the
CSOM, UTI and CF-chronic groups might be
explained by previous antibiotic use. When com-
paring the present antimicrobial resistance data
with those of the worldwide SENTRY antimicro-
bial surveillance programme in paediatric iso-
lates, a two-fold to ten-fold higher percentage of
P. aeruginosa antimicrobial resistance to ciproﬂox-
acin, ceftazidime, piperacillin, tobramycin and
polymyxin was observed in the European isolates
as compared to our isolates [35]. Low resistance
levels might be the result of a strict antibiotic
prescription policy in The Netherlands.
A higher percentage (22.5%) of antimicrobial
resistance was noticed among clonal isolates than
among other isolates in the CF-chronic group. The
patients carrying clonal isolates were signiﬁcantly
older, suggesting the possibility that the cumula-
tive administered dose of antimicrobial therapy
was higher. In addition, clonal isolates might
possess intrinsic resistance mechanisms unrelated
to previous antimicrobial therapy, which facilitate
survival, as the majority of clonal isolates were
not antibiotic-resistant.
In conclusion, a large diversity in phenotypes
and genotypes was noted in 202 P. aeruginosa
isolates from ﬁve distinct paediatric patient
groups susceptible to P. aeruginosa infection. Iso-
lates of the CF-chronic group were signiﬁcantly
less diverse than those of the other groups; clonal
isolates seemed to be restricted to CF patients.
Transmission of clonal CF isolates to other patient
groups was not observed, suggesting that this
clone has an as yet unknown selective advantage
for colonizing CF patients as compared with other
patients.
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